ABSTRACT
Objective Determine whether statin-associated DM is reported more frequently in women than men in post-marketing adverse drug event (ADE) surveillance.
Design Retrospective pharmacovigilance analysis
Data source Publicly available FDA Adverse Event Reporting System (FAERS) from January 1997 through December 2023.
Setting Real-world spontaneously reported ADEs in the United States.
Participants Community patients reporting statin ADEs during the study period.
Interventions/exposures Adverse drug event reports that included at least one statin.
Main outcome measures Proportional reporting ratio to identify increased rates of statin-associated DM events in women and men compared with all other medications, and reporting odds ratio to compare reporting rates in women vs. men.
Results A total of 18,294,814 ADEs were reported during the study period. Among statin-associated ADEs, 14,897/519,209 (2.9%) reports mentioned DM in women compared with 7,412/489,453 (1.5%) in men, which were both significantly higher than background (0.6%). Statins were primary-or secondary-suspected cause of the ADE significantly more often in women than men (59.8 vs. 28.7%), and reporting rates were disproportionately higher in women than in men for all statins. (reporting odds ratio 1.9 [95% CI 1.9-2.0]). The largest difference in reporting of statin-associated DM between women and women was observed with atorvastatin.
Conclusions Analysis post-marketing spontaneous ADE reports demonstrated a higher reporting rate of DM-associated with statin use compared to other medications with a significantly higher reporting rate in women compared to men. Future studies should consider mechanisms of statin-associated DM moderated by sex.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The raw data used in this study is publicly available at https://open.fda.gov/data/faers/). The drug names and ingredients of FDA approved products is available at https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files. The MedDRA terminology is available with a license at https://www.meddra.org/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: None
Data availability statement
The raw data used in this study is publicly available at https://open.fda.gov/data/faers/). The drug names and ingredients of FDA approved products is available at https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files. The MedDRA terminology is available with a license at https://www.meddra.org/. The R mdsstat analysis package is at https://rdrr.io/cran/mdsstat/. Analysis code and access to our FAERS BigQuery repository containing linked versions of the above resources are available on reasonable request.
